HIV & AIDS

HIV vaccine research must consider various immune responses

Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility ...

HIV & AIDS

Novel intravaginal ring shows promise in HIV prevention

A new 90-day intravaginal ring has been developed—that for the first time—enables the long-lasting vaginal delivery of tenofovir (TFV), the only topical prophylactic shown to be effective at reducing the sexual transmission ...

HIV & AIDS

NIH-funded analysis estimates effective PrEP dosing

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP. The level ...

page 3 from 4